A Look At IQVIA Holdings (IQV) Valuation After Strong 2025 Results And New Obesity Research Collaboration

Simply Wall St.

02/23

IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2613207987"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613207987\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613207987?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159","is_english":true,"pubTime":"2026-02-23 15:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613207987","market":"nz","top_or_hot":-1,"title":"A Look At IQVIA Holdings (IQV) Valuation After Strong 2025 Results And New Obesity Research Collaboration","media":"Simply Wall St.","content":"<div>\n<p>IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/a-look-at-iqvia-holdings-iqv-valuation-after-strong-2025-res\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At IQVIA Holdings (IQV) Valuation After Strong 2025 Results And New Obesity Research Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At IQVIA Holdings (IQV) Valuation After Strong 2025 Results And New Obesity Research Collaboration\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-02-23 15:20</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/a-look-at-iqvia-holdings-iqv-valuation-after-strong-2025-res\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/a-look-at-iqvia-holdings-iqv-valuation-after-strong-2025-res\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/a-look-at-iqvia-holdings-iqv-valuation-after-strong-2025-res","article_id":"2613207987","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/a-look-at-iqvia-holdings-iqv-valuation-after-strong-2025-res","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613207987","pubTimestamp":1771831219,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical Research Institute.\nSee our latest analysis for IQVIA Holdings.\nDespite the recent obesity research collaboration and solid year-end results, IQVIA Holdings’ share price has come under pressure, with a 30 day share price return of 29.62% and a 1 year total shareholder return of 13.31%. This...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IQV":"艾昆纬","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4588":"碎股","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4530":"医药外包概念","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"在2025年强劲业绩和新的肥胖研究合作之后，看看IQVIA Holdings(IQV)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical Research Institute. See our latest analysis for IQVIA Holdings. Despite the recent obesity research collaboration and solid year-end results, IQVIA Holdings’ share price has come under pressure, with a 30 day share price return of 29.62% and a 1 year total shareholder return of 13.31%. This suggests that recent momentum has weakened, even as longer term performance has held up somewhat better. If this news has you thinking about where else growth in healthcare and data could come from, it might be worth scanning our list of 27 healthcare AI stocks for fresh ideas beyond IQVIA. With IQVIA now trading well below recent levels despite near double digit growth and a sizeable implied discount to analyst targets, you have to ask: is this a reset that opens an opportunity, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 33.8% Undervalued At a last close of $165.62 against a widely followed fair value of $250.00, the current price sits well below what this narrative assumes.  Record R&D Solutions backlog and strong sequential increases in qualified pipeline and RFP flow indicate sustained demand for outsourced clinical research, particularly in oncology, cell & gene therapies, and novel therapeutic areas, which should translate into resilient, long-term contracted revenues and improved earnings visibility.  Read the complete narrative. Want to see what sits behind that confidence in contracted work and earnings visibility? The narrative leans on measured revenue growth, firmer margins, and a future earnings multiple that assumes investors remain willing to pay a premium for this model. Result: Fair Value of $250.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if CRO pricing pressures deepen or if high leverage, with net debt at 3.61x EBITDA, starts to constrain IQVIA’s flexibility. Find out about the key risks to this IQVIA Holdings narrative. Next Steps If this mix of optimism and caution around IQVIA feels familiar, take a moment now to look through the numbers yourself and weigh up 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at one company. Use the screener to line up your next potential moves today.  Target steady income opportunities by scanning 15 dividend fortresses that may help anchor your returns when growth names feel uncertain. Hunt for quality at a potential discount by reviewing 54 high quality undervalued stocks that pair fundamentals with what our model flags as attractive pricing. Prioritise peace of mind by focusing on 87 resilient stocks with low risk scores that our scoring suggests carry more measured risk profiles than the broader market.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}